Celltrion-IQure, Exclusive Domestic Sales of Donepezil Patch for Alzheimer's Dementia Treatment

Incheon Songdo Celltrion Plant 2 Overview. / Incheon = Photo by Kim Hyun-min kimhyun81@

[Asia Economy Reporter Seo So-jung] Celltrion announced on the 20th that it has signed an exclusive domestic sales contract for the Donepezil patch 'Donerion Patch,' developed jointly with iCure for the treatment of Alzheimer's dementia.

Donerion Patch submitted a marketing authorization application to the Ministry of Food and Drug Safety (MFDS) in April this year, and upon approval, it will become the world's first Donepezil patch.

In 2017, Celltrion signed a domestic joint distribution rights contract with iCure for the Donepezil patch, but with this exclusive sales contract, it has secured the right to sell the product exclusively in Korea for about 12 years. iCure is responsible for the production and supply of the Donepezil patch.

Until now, Donepezil has only been commercialized as an oral formulation taken once daily due to difficulties in formulation development. Donerion Patch is an improved new drug developed as a twice-weekly patch, which Celltrion explained improves medication adherence and convenience compared to oral drugs.

A Celltrion official said, "If Donerion Patch receives MFDS approval, it will secure the status as the world's first Donepezil patch, and we expect to highlight its differentiation from existing formulations not only in the domestic market but also globally, securing a leading position."

This content was produced with the assistance of AI translation services.